Market Waking Up to Abbvie's (ABBV) Strong Pipeline - Jefferies
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/13/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Goldman Sachs Raises PT on Abbvie (ABBV) to $52
April 29, 2013 10:45 AM EDTGoldman Sachs today maintained a Buy rating on Abbvie (NYSE: ABBV) and raised its price target to $52.00 (from $45.00). Analyst Jami Rubin said he had greater confidence in Humira growth and in Abbvie's pipeline.
"We estimate that in a best case... More
Abbvie, Inc. (ABBV) Tops Q1 EPS by 1c; Reaffirms Outlook
April 26, 2013 7:52 AM EDT(Updated - April 26, 2013 7:59 AM EDT)
AbbVie (NYSE: ABBV) reported Q1 EPS of $0.68, $0.01 better than the analyst estimate of $0.67. Revenue for the quarter came in at $4.33 billion, versus $4.17 billion reported last year.
On an operational basis, sales increased 5.1 percent, excluding a 1.4 percent unfavorable impact from foreign exchange rate... More
